Trial Profile
A Randomised, Double-blind, Parallel-group, Placebo controlled, Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Tesnatilimab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Dec 2022 This trial has been completed in Poland according to European Clinical Trials Database record.
- 10 Dec 2022 This trial has been completed in Belgium (End Date: 23 May 2013) according to European Clinical Trials Database record.
- 21 Dec 2012 Planned End Date changed from 1 Jan 2014 to 1 Jun 2013 as reported by ClinicalTrials.gov record.